Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05800665 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

A Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, sponsored by Genentech.

Recruiting
Registry status
Phase 1
Development phase
210
Enrollment target
20
Study locations

NCT05800665: Recruiting Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, sponsored by Genentech.

NCT05800665 is a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer that is actively recruiting participants, run by Genentech. The registered enrollment target is 210 participants, above the 181-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05800665, a Phase 1 study of Metastatic Prostate Cancer and Advanced Prostate Cancer, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 1
Development phase
210 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

Conditions Studied

Metastatic Prostate Cancer Advanced Prostate Cancer

Interventions

  • DRUG RO7656594

Study Locations (20)

Other

  • Centre Léon Bérard - Lyon
  • Institut Paoli Calmettes - Marseille
  • Seoul National University Hospital - Seoul
  • Severance Hospital Yonsei University Health System - PPDS - Seoul
  • Asan Medical Center - PPDS - Seoul
  • Samsung Medical Center - PPDS - Seoul
  • Hospital Universitario Vall d'Hebron - PPDS - Barcelona
  • Clinica Universidad de Navarra-Madrid - Madrid

New South Wales

  • St Vincent's Hospital Sydney - Darlinghurst
  • Macquarie University Hospital - New South Wales

Victoria

  • Monash Health Monash Medical Centre - Clayton
  • Austin Hospital - Heidelberg

Arizona

  • HonorHealth - Scottsdale

Connecticut

  • Yale Cancer Center - New Haven

Florida

  • Sarah Cannon Research Institute @ Florida Cancer - Orlando

Illinois

  • University of Illinois Hospital & Health Sciences System - Chicago

Texas

  • SCRI Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2023-05-02
Est. Completion 2027-06-30
Phase Phase 1
Genentech

332 total trials

What NCT05800665 shows while recruiting

NCT05800665 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (16% higher).

The record links to 2 conditions, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which RO7656594 is the first listed.

NCT05800665 names 20 study sites across 11 states, led by Other, New South Wales, Victoria.

Frequently Asked Questions

What is clinical trial NCT05800665 about?

NCT05800665 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.

What is the current status of trial NCT05800665?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2023-05-02. Estimated completion is 2027-06-30.

What conditions does trial NCT05800665 study?

This clinical trial studies the following conditions: Metastatic Prostate Cancer, Advanced Prostate Cancer.

What interventions are being tested in trial NCT05800665?

The interventions under investigation include: RO7656594 (DRUG).

Who is sponsoring clinical trial NCT05800665?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05800665 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05800665's enrollment target sits among peer trials

210 9th of 41 higher than 33 of 41 other Metastatic Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

  • NCT03544489 · 210 participants · Phase 2

    Effectiveness of Exercise After an ICD

  • NCT04408430 · 210 participants · NA

    The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05800665

Source: ClinicalTrials.gov NCT05800665, the US trial registry maintained by the National Library of Medicine. NCT05800665 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.